KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $115.6 billion.

  • Pfizer's Total Liabilities fell 889.0% to $115.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $115.6 billion, marking a year-over-year decrease of 889.0%. This contributed to the annual value of $124.9 billion for FY2024, which is 897.44% down from last year.
  • As of Q3 2025, Pfizer's Total Liabilities stood at $115.6 billion, which was down 889.0% from $117.1 billion recorded in Q2 2025.
  • Pfizer's 5-year Total Liabilities high stood at $137.2 billion for Q4 2023, and its period low was $10.4 billion during Q4 2021.
  • Its 5-year average for Total Liabilities is $103.5 billion, with a median of $115.6 billion in 2025.
  • In the last 5 years, Pfizer's Total Liabilities plummeted by 1214.17% in 2021 and then skyrocketed by 42468.05% in 2023.
  • Over the past 5 years, Pfizer's Total Liabilities (Quarter) stood at $104.0 billion in 2021, then decreased by 2.62% to $101.3 billion in 2022, then skyrocketed by 35.47% to $137.2 billion in 2023, then dropped by 8.97% to $124.9 billion in 2024, then dropped by 7.42% to $115.6 billion in 2025.
  • Its last three reported values are $115.6 billion in Q3 2025, $117.1 billion for Q2 2025, and $117.4 billion during Q1 2025.